StreetInsider.com News Articles

Form 424B5 Baird Medical Investment

Thu, 24 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260924/27102219.html

Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 15 Sep 2026 08:00:00 -0400

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City.

H.C. Wainwright 28th Annual Global Investment Conference
Date: Wednesday, September 16, 2026
Time: 11:30 a.m. ET
Location: Lotte New York Palace Hotel, New York City

A live webcast of the presentation will be available through the Investor Relations section of

Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 15 Sep 2026 08:00:00 -0400

H.C. Wainwright 28th Annual Global Investment Conference
Date: Wednesday, September 16, 2026
Time: 11:30 a.m. ET
Location: Lotte New York Palace Hotel, New York City

A live webcast of the presentation will be available through the Investor Relations section of

Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology

Mon, 14 Sep 2026 08:00:00 -0400

Company Engaged with Interventional Radiology Community at Leading Global Congress in Copenhagen

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today highlighted its participation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, held at the Bella Center Copenhagen.

Throughout the congress, Baird Medical showcased its Microwave Ablation (MWA)

Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology

Mon, 14 Sep 2026 08:00:00 -0400

Company Engaged with Interventional Radiology Community at Leading Global Congress in Copenhagen

Throughout the congress, Baird Medical showcased its Microwave Ablation (MWA)

Baird Medical posts 25% revenue gain and slim profit in H1 2026

Thu, 03 Sep 2026 08:03:57 -0400

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) reported preliminary unaudited revenue of approximately $9.9 million for the six months ended June 30, 2026, a 24.6% increase from $8.0 million in the same period a year earlier, according to a company press release.

The company attributed the revenue increase to growth outside of China, including in the United States, as well as licensing revenue. Approximately two-thirds of revenue came from markets outside of the People's Republic of China, with Hong Kong and the U.S. identified as the main contributing regions. The U.S. accounted for approximately 27% of first-half revenue, compared with less

Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026

Thu, 03 Sep 2026 08:00:00 -0400

Revenue increase driven by significant growth in the United States and other strategic markets

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), today announced preliminary unaudited financial results for the six months ended June 30, 2026.

Revenue for the first half of 2026 was approximately $9.9 million, an increase of 24.6% over $8.0 million reported for the six months ended June 30, 2025. The increase in revenue was primarily attributable to growth outside of the People’s Republic of China, including in the United States, as well

Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026

Thu, 03 Sep 2026 08:00:00 -0400

Revenue increase driven by significant growth in the United States and other strategic markets

Baird Medical wins two Pakistan product registrations for ablation gear

Thu, 20 Aug 2026 08:30:34 -0400

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) announced that its BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan (DRAP).

The registrations build on the company's existing presence in Pakistan, where it announced regulatory approvals and initial commercial availability at the Armed Forces Institute of Radiology & Imaging in January 2026.

Haimei Wu, Chairwoman and CEO of Baird Medical, said in a statement: "Building a meaningful global presence requires more than entering new markets. Establishing the infrastructure to support sustained clinical adoption of our technologies is critical to our long-term

Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan

Thu, 20 Aug 2026 08:30:00 -0400

Registrations cover the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle

NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), announced that the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan (“DRAP”), further supporting the Company’s commercial activities in the country.

The registrations build on Baird Medical’s existing presence in Pakistan, where the Company announced regulatory approvals and initial commercial availability at the Armed Forces Institute of Radiology & Imaging (“AFIRI”) in

Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan

Thu, 20 Aug 2026 08:30:00 -0400

Registrations cover the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle

Form 424B3 Baird Medical Investment

Tue, 18 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260818/26940594.html

Form 424B3 Baird Medical Investment

Tue, 18 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260818/26940594.html

Form EFFECT Baird Medical Investment

Tue, 18 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260818/26940115.html

Form EFFECT Baird Medical Investment

Tue, 18 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260818/26940115.html

Form EFFECT Baird Medical Investment

Tue, 18 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260818/26940126.html

Form EFFECT Baird Medical Investment

Tue, 18 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260818/26940126.html

Baird Medical and Alpmed partner to develop IRE ablation technology

Mon, 10 Aug 2026 08:30:18 -0400

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) and Tianjin Yuanshan Medical Technology Co., Ltd., operating under the brand name Alpmed, have signed a strategic cooperation agreement to jointly develop and commercialize irreversible electroporation (IRE) technology across international markets, according to a press release.

IRE is a non-thermal ablation technique that uses electrical pulses to destroy targeted tissue while preserving nearby structures such as blood vessels and nerves.

Under the agreement, Baird Medical will lead global regulatory processes and hold worldwide commercialization rights for the co-developed IRE product. The companies plan to submit a 510(k) application to the U.S. Food and Drug Administration

Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally

Mon, 10 Aug 2026 08:30:00 -0400

Agreement combines Baird Medical's clinical, regulatory, and global commercialization expertise with Alpmed's leadership in IRE technology
Collaboration will advance technology development, global regulatory approvals, commercialization, and clinical adoption across key international markets, including the United States

NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”) and Tianjin Yuanshan Medical Technology Co., Ltd., operating under the Alpmed brand (“Alpmed”), a China-based innovator in irreversible electroporation (“IRE”) technology, announced the signing of a strategic cooperation agreement to establish a long-term partnership

Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally

Mon, 10 Aug 2026 08:30:00 -0400

Agreement combines Baird Medical's clinical, regulatory, and global commercialization expertise with Alpmed's leadership in IRE technology
Collaboration will advance technology development, global regulatory approvals, commercialization, and clinical adoption across key international markets, including the United States

Form POS AM Baird Medical Investment

Thu, 06 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260806/26883687.html

Form POS AM Baird Medical Investment

Thu, 06 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260806/26883687.html

Form F-3/A Baird Medical Investment

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883334.html

Form F-3/A Baird Medical Investment

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883334.html

Form 3 Baird Medical Investment For: Mar 18 Filed by: ExcelFin SPAC LLC

Fri, 31 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260731/26851536.html